Consensus Virtual Screening Identified [1,2,4]Triazolo[1,5-b]isoquinolines As MELK Inhibitor Chemotypes.

"Conflict of interest The authors declare that they have no conflict of interest."

"The authors thank their colleagues at the MS Metabolomics Laboratory Core Facility at RCNS for the HRMS measurements, and Károly Héberger for helpful discussions. The work of A.R. is supported by the National Research, Development and Innovation Office of Hungary (OTKA, contract no. PD134416). The work of D.B. is supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences and the ÚNKP‐21‐5 New National Excellence Program of the Ministry for Innovation and Technology. Dávid Bajusz received his PhD in chemistry from the Budapest University of Technology and Economics. Since 2017, he has been employed as a postdoctoral researcher in the Medicinal Chemistry Research Group, led by György M. Keserű, at the Research Centre for Natural Sciences in Budapest, Hungary. His main research interests include medicinal chemistry, computational drug discovery and cheminformatics. He is involved in several international collaborative research efforts in these areas, focusing on drug discovery for pharmaceutical targets of oncological indications, as well as methodological innovations in computational drug design. He has co‐authored more than 40 publications, as well as three book chapters in major reference works, and was awarded for his accomplishments with the Junior Prima Prize in the category of Hungarian Science in 2019. In addition to his research work, he has co‐organized several conferences and regularly provides peer reviews for major scientific journals of his field. Since 2020, he is a recipient of the János Bolyai Research Scholarship of the Hungarian Academy of Sciences."